MEP Antibacterial Screening Service

Isoprenoids comprise one of the most diverse classes of compounds found in nature.  With over 33,000 different isoprenoids identified to date, they exhibit a broad range of structural complexity and are involved in a variety of biological functions.  Isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) are the precursors for all isoprenoid compounds with two unrelated essential pathways found in nature for their biosynthesis.  Until recently it was assumed that all organisms required the mevalonate (MVA) pathway for IPP and DMAPP biosynthesis.  An alternate pathway to IPP and DMAPP, the methylerythritol phosphate (MEP) pathway, is utilized by most bacteria, including all Gram-negatives and many Gram-positives, and plant chloroplasts while the MVA pathway is found in humans, plant cytosol and some Gram-positive bacteria.  Due to this natural distribution, the MEP pathway represents a promising target for development of novel antibacterial agents and herbicides.

  • Echelon has 25 years of assay development expertise and 15 years experience in the MEP field.
  • Your samples are cataloged and stored according to your requirements.
  • The MEP Screening Service will run each sample in duplicate.
  • Results are provided as an average of the duplicate points in uM LPA .
  • Usually results are provided 2 weeks from receipt of samples. We can accommodate tighter schedules if needed.

Contact us for a quote on your custom assay service.

Description

Contact Us

Fill out the form below to receive a full quote for this service.

Publications

Publications for this service are based off of the MEP Synthase Inhibitor Screen (catalog number K-2000C), the product used for this assay service.

1) Bochar, D.A.; Freisen, J.A.; Stauffacher, C.V. and Rodwell, V.W.(1999) Comprehensive Natural Products Chemistry,(Cane, D. Ed.) Pergamon Press, Oxford, pp. 15-44.
2) Sacchettini, J.C. and Poulter, C.C. (1997) Science, 277(5333), 1788-9.
3) Testa, C.A.; Brown, M.J. (2003) Current Pharmceutical Biotechnology, 4, 248-259.
4) Koppisch, A.T.; Fox, D.T.; Blagg, B.; Poulter, C.D. (2002), Jan 8; 41 (1), 236-43.

Shopping Cart
Scroll to Top